Close Navigation
About ArixStrategy
OverviewInvestment caseNewsResultsDocumentsEventsCalendarAnalystsStock infoContact
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
Overlay

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

11th December 2022

Portfolio

This post references, or is about Harpoon. Find out more by clicking below

San Francisco, CA, US

Useful Tools

Download, print or share this article

Print Print Article Email Email Article
Print Save Article
Share Article
TwitterTwitterLinkedInLinkedInFacebookFacebook

Arix Bioscience

About Arix

The Team

Portfolio

Insights

News & Events

Contact

Investor Relations

Results Centre

Financial Calendar

Regulatory News

Document Library

Analysts & Advisors

Shareholder Information

Meta

Privacy Policy

Terms of use

Cookie Policy

Stay up to date

Sign up to receive regulatory news and results

Subscribe
Arix Bioscience
linkedintwitter

Arix Bioscience plc, registered in England and Wales with company number 09777975

Registered office: Duke Street House, 50 Duke Street, London, W1K 6JL, United Kingdom

Website by Ether